Dr. Oz Grilling In Senate Tops 2014 Dietary Supplement News
This article was originally published in The Tan Sheet
Executive Summary
Articles on the potential that debate around the benefits of fish oils will damage consumer regard for omega-3 supplements, FDA’s guidance on distinguishing between liquid supplements and conventional beverages and Daniel Fabricant’s exit from FDA’s supplement regulation office also were highly read in 2014.
You may also be interested in...
Fabricant Ends Eventful Service In FDA Supplement Regulation To Head NPA
Daniel Fabricant will be the CEO of NPA, and leave his post as director of FDA’s Division of Dietary Supplement Programs, the association announced April 8.
Omega-3 Questions Could Pull Plug On Sales Growth
Pharma firms’ introduction and wide promotion of Rx drugs containing EPA or DHA acids and aimed at improving cardiovascular health were expected to boost omega-3 supplement sales, but negative research results reported over the past year could diminish consumers’ regard for the nutrients’ benefits.
Omega-3 Petition Seeks Unqualified Blood Pressure, CHD Claims
The trade group Global Organization for EPA and DHA Omega-3 petitions FDA for an unqualified health claim related to reduced blood pressure as a surrogate marker for coronary heart disease risk.